Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.30
Bid: 6.10
Ask: 6.50
Change: 0.05 (0.80%)
Spread: 0.40 (6.557%)
Open: 6.25
High: 6.30
Low: 6.25
Prev. Close: 6.25
KMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kromek receives $2.1m security screening order

26 Mar 2024 07:00

RNS Number : 2389I
Kromek Group PLC
26 March 2024
 

26 March 2024

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek receives $2.1m security screening order

New order from long-standing OEM customer

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has received a $2.1m order from an existing US-based OEM customer that is an emerging leader and global company in the homeland security marketplace.

 

The order is for the supply of key detector components for incorporation into the customers' advanced security screening system for the detection of explosives. Delivery will commence in the current year and complete in the first half of FY 2025. The Group has been supplying this customer since 2017 when it was awarded a five-year delivery contract, following the completion of an R&D phase to design components to meet the customer's requirements, and it expects to enter another long-term delivery contract.

 

Arnab Basu, CEO of Kromek, said: "We are pleased to have received this latest order from a long-standing customer in the security screening market. It demonstrates the strength of our advanced imaging business where, after an initial design phase, we continue to receive orders for years to come. It also adds to the growing pipeline for FY 2025, which we expect to be a year of further growth. In addition, with the global aviation market now recovering, we expect another long-term delivery contract in due course, which will provide enhanced visibility into 2025 and beyond. We look forward to updating the market on our progress." 

 

 

For further information, please contact: 

? 

Kromek Group plc 

Arnab Basu, CEO 

Paul Farquhar, CFO 

+44 (0)1740 626 060

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)? 

? 

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance 

Tim Redfern - ECM 

+44 (0)20 7220?0500 

 

Michael Johnson/Tamar Cranford-Smith - Sales

 

Gracechurch Group (Financial PR) 

Harry Chathli/Claire Norbury/Henry Gamble

+44 (0)20 4582 3500

 

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEIEFIELSEFD
Date   Source Headline
13th Jan 20217:01 amRNSFunding to advance Bio-Threat Detection solution
13th Jan 20217:00 amRNSInterim Results
7th Jan 202111:05 amRNSSecond Price Monitoring Extn
7th Jan 202111:01 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSDirectorate Changes
14th Dec 202012:45 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSNotice of Results
8th Dec 20207:00 amRNSContract extensions for D3S products
3rd Dec 20207:00 amRNSKromek launches the D5 RIID radiation detector
2nd Nov 20207:00 amRNSKromek wins new sector-leading global OEM customer
2nd Nov 20207:00 amRNSResult of AGM
29th Oct 20207:00 amRNSDirectorate Change
14th Oct 20207:00 amRNSKromek CZT technology to improve cancer surgery
9th Oct 20204:41 pmRNSSecond Price Monitoring Extn
9th Oct 20204:36 pmRNSPrice Monitoring Extension
8th Oct 20205:28 pmRNSHolding(s) in Company
8th Oct 20204:44 pmRNSNotice of AGM and Publication of Annual Report
8th Oct 202012:58 pmRNSDirector Share Purchase
8th Oct 20207:00 amRNSAppointment of Non-executive Director
7th Oct 202011:13 amRNSDirector Share Purchase
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20207:00 amRNSFinal Results
28th Sep 20203:00 pmRNSHolding(s) in Company
17th Sep 20201:53 pmRNSHolding(s) in Company
27th May 20207:00 amRNSKromek awarded new DARPA bio-surveillance contract
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
1st May 20209:05 amRNSSecond Price Monitoring Extn
1st May 20209:00 amRNSPrice Monitoring Extension
1st May 20207:00 amRNSFull Year Trading Update and Response to COVID-19
27th Apr 202010:57 amRNSHolding(s) in Company
21st Apr 20207:00 amRNSKromek receives Queen’s Award
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSKromek to produce ventilators to fight COVID-19
20th Mar 202010:52 amRNSHolding(s) in Company
18th Feb 20204:15 pmRNSHolding(s) in Company
27th Jan 202012:42 pmRNSSite visit by International Trade Secretary
9th Jan 20204:55 pmRNSHolding(s) in Company
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20197:00 amRNSDirector Share Purchase
12th Dec 20197:00 amRNSDirector Share Purchases
11th Dec 20197:00 amRNSInterim Results
5th Dec 20197:00 amRNSNotice of Results
4th Dec 20195:25 pmRNSHolding(s) in Company
26th Sep 20191:14 pmRNSResult of AGM
24th Sep 20197:00 amRNSKromek awarded two contracts for D3S products
30th Aug 20191:50 pmRNSNotice of AGM and Publication of Annual Report
1st Jul 20197:00 amRNSNew contracts for D3S in UK, US and Europe

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.